GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acutus Medical Inc (NAS:AFIB) » Definitions » Debt-to-EBITDA

Acutus Medical (Acutus Medical) Debt-to-EBITDA : 0.26 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Acutus Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Acutus Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.58 Mil. Acutus Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $35.90 Mil. Acutus Medical's annualized EBITDA for the quarter that ended in Dec. 2023 was $150.04 Mil. Acutus Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Acutus Medical's Debt-to-EBITDA or its related term are showing as below:

AFIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18.85   Med: -0.51   Max: 1.1
Current: -18.85

During the past 6 years, the highest Debt-to-EBITDA Ratio of Acutus Medical was 1.10. The lowest was -18.85. And the median was -0.51.

AFIB's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs AFIB: -18.85

Acutus Medical Debt-to-EBITDA Historical Data

The historical data trend for Acutus Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acutus Medical Debt-to-EBITDA Chart

Acutus Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.57 -0.44 -0.43 1.10 -7.22

Acutus Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 -0.72 -0.62 -0.93 0.26

Competitive Comparison of Acutus Medical's Debt-to-EBITDA

For the Medical Devices subindustry, Acutus Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acutus Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Acutus Medical's Debt-to-EBITDA falls into.



Acutus Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Acutus Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.582 + 35.897) / -5.329
=-7.22

Acutus Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.582 + 35.897) / 150.04
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Acutus Medical  (NAS:AFIB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Acutus Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Acutus Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Acutus Medical (Acutus Medical) Business Description

Traded in Other Exchanges
N/A
Address
2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.
Executives
Takeo Mukai officer: Interim CFO C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Jason K Garland director 10000 WEHRLE DRIVE, CLARENCE NY 14031
Kevin Mathews officer: SVP, Global Sales C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Charlie Piscitello officer: Chief People Officer 2210 FARADAY AVE #100, CARLSBAD CA 92008
Tom Sohn officer: SVP, Gen. Counsel & Secretary 2210 FARADAY AVE #100, CARLSBAD CA 92008
R Scott Huennekens director C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Niamh Louise Pellegrini director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James E Flynn director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Orbimed Capital Gp Iv Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
John F Sheridan director C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
David Roman officer: SVP & Chief Financial Officer ACUTUS MEDICAL, INC., 2210 FARADAY AVE, SUITE 100, CARLSBAD CA 92008